EU/3/20/2247

Table of contents

About

On 28 February 2020, orphan designation EU/3/20/2247 was granted by the European Commission to IQVIA RDS Ireland Limited, Ireland, for 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate (also known as CPI-0610) for the treatment of myelofibrosis.

The sponsorship was transferred to AdRes EU B.V Netherlands, in June 2020.

Key facts

Active substance
2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl)acetamide monohydrate
Disease / condition
Treatment of myelofibrosis
Date of first decision
28/02/2020
Outcome
Positive
EU designation number
EU/3/20/2247

Sponsor's contact details

AdRes EU B.V.
Pietersbergweg 283
1105 BM Amsterdam
Noord-Holland
Netherlands
Tel: + 31207920069
​​​​​​​E-mail: Office@adreseu.nl

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating